DaVita Inc.
DVAHealthcareNASDAQMedical Care Facilities
Scan Results
Daily timeframeDaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. Valued at $11.74B, DVA is a large-cap name in its sector. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers.
Market Cap
$11.74B
Beta
0.83
P/E (TTM)
15.61
P/E (Fwd)
10.67
EPS (TTM)
$11.79
EPS (Fwd)
$17.25
ROE
88.5%
ROA
7.5%
Cash
$688.9M
Total Debt
$13.41B
Free CF
$1.04B
52W Change
36.8%
Annual Financials
Cash vs Debt
Where DVA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, DVA finished 0.24% below its 150-day moving average ($179.83) and 9.75% above its 200-day moving average ($163.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DVA overbought or oversold?
At the September 3, 2026 close, DVA's RSI(14) was 50.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, DVA has $688.9M in cash with $13.41B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $1.04B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 88.5% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $11.61B to $13.64B.
DaVita Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence DaVita Inc.'s trajectory.